Brown adipose tissue dysfunction promotes heart failure via a trimethylamine N-oxide-dependent mechanism
Yohko Yoshida,Ippei Shimizu,Atsuhiro Shimada,Keita Nakahara,Sachiko Yanagisawa,Minoru Kubo,Shinji Fukuda,Chiharu Ishii,Hiromitsu Yamamoto,Takamasa Ishikawa,Kuniyuki Kano,Junken Aoki,Goro Katsuumi,Masayoshi Suda,Kazuyuki Ozaki,Yutaka Yoshida,Shujiro Okuda,Shigeo Ohta,Shiki Okamoto,Yasuhiko Minokoshi,Kanako Oda,Toshikuni Sasaoka,Manabu Abe,Kenji Sakimura,Yoshiaki Kubota,Norihiko Yoshimura,Shingo Kajimura,Maria Zuriaga,Kenneth Walsh,Tomoyoshi Soga,Tohru Minamino
DOI: https://doi.org/10.1038/s41598-022-19245-x
2022-09-01
Abstract:Low body temperature predicts a poor outcome in patients with heart failure, but the underlying pathological mechanisms and implications are largely unknown. Brown adipose tissue (BAT) was initially characterised as a thermogenic organ, and recent studies have suggested it plays a crucial role in maintaining systemic metabolic health. While these reports suggest a potential link between BAT and heart failure, the potential role of BAT dysfunction in heart failure has not been investigated. Here, we demonstrate that alteration of BAT function contributes to development of heart failure through disorientation in choline metabolism. Thoracic aortic constriction (TAC) or myocardial infarction (MI) reduced the thermogenic capacity of BAT in mice, leading to significant reduction of body temperature with cold exposure. BAT became hypoxic with TAC or MI, and hypoxic stress induced apoptosis of brown adipocytes. Enhancement of BAT function improved thermogenesis and cardiac function in TAC mice. Conversely, systolic function was impaired in a mouse model of genetic BAT dysfunction, in association with a low survival rate after TAC. Metabolomic analysis showed that reduced BAT thermogenesis was associated with elevation of plasma trimethylamine N-oxide (TMAO) levels. Administration of TMAO to mice led to significant reduction of phosphocreatine and ATP levels in cardiac tissue via suppression of mitochondrial complex IV activity. Genetic or pharmacological inhibition of flavin-containing monooxygenase reduced the plasma TMAO level in mice, and improved cardiac dysfunction in animals with left ventricular pressure overload. In patients with dilated cardiomyopathy, body temperature was low along with elevation of plasma choline and TMAO levels. These results suggest that maintenance of BAT homeostasis and reducing TMAO production could be potential next-generation therapies for heart failure.